Table 1.
LCIG n = 8 | Oral n = 13 | p‐value | |
---|---|---|---|
Gender [m/f] | 5/3 | 6/7 | .55 |
Age [years] | 69,8 ± 6,7 | 72,8 ± 6,8 | .27 |
PD duration [years] | 19,5 ± 6 | 13,7 ± 9,4 | .06 |
Hoehn & Yahr | 4 ± 1,3 | 4 ± 0,7 | .63 |
UPDRS part III | 21,8 ± 16,3 | 28,7 ± 13,9 | .35 |
LDD [mg/day] | 2,342 ± 956 | 865.8 ± 567 | .0021 |
LEDD [mg/day] | 2,360 ± 1,064 | 1,051 ± 662 | .0034 |
LCIG duration [months] | 37,4 ± 32,2 | n/a | n/a |
LDD increase with LCIG [mg/day] | 963,1 ± 740,8 | n/a | n/a |
Pyridoxine [3.6–18 μg/L] | 2.4 ± 1.4 | 5.5 ± 3.5 | .01 |
Cobalamin [191–663 ng/L] | 267.3 ± 85 | 321.4 ± 143.5 | .48 |
Folate [4.6–18.7 μg/L] | 7.8 ± 4.0 | 8.1 ± 3.0 | 1 |
Homocysteine [6.3–15.1 μmol/L] | 33.7 ± 25 | 22.2 ± 6.9 | .34 |